Alnylam Pharmaceuticals (LTS:0HD2) Accumulated Depreciation: $ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HD2 Alnylam Pharmaceuticals Inc LTS:0HD2
65 GF Score
Price $244.32
GF Value $541.78
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Alnylam Pharmaceuticals Accumulated Depreciation?

Alnylam Pharmaceuticals LTS:0HD2 +0.25% 65 Accumulated Depreciation is $ Mil as of Jun. 2026. GuruFocus rates LTS:0HD2 with a GF Score™ of 65/100 and a GF Value™ of $541.78 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Alnylam Pharmaceuticals's annual accumulated depreciation increased from Dec. 2023 ($-223 Mil) to Dec. 2024 ($-270 Mil) and increased from Dec. 2024 ($-270 Mil) to Dec. 2025 ($-323 Mil).

Alnylam Pharmaceuticals Accumulated Depreciation Related Terms

Alnylam Pharmaceuticals Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Alnylam Pharmaceuticals's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals Accumulated Depreciation Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -140.42 -173.45 -223.08 -270.36 -322.70

Alnylam Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
LTS:0HD2
65GF Score
Alnylam Pharmaceuticals Inc LTS:0HD2
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alnylam Pharmaceuticals Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $ Mil mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a Accumulated Depreciation of $ Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Accumulated Depreciation too high?
Alnylam Pharmaceuticals' current Accumulated Depreciation is $ Mil. Overall, Alnylam Pharmaceuticals has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Accumulated Depreciation compare to RPRX and INSM?
Alnylam Pharmaceuticals' Accumulated Depreciation of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Accumulated Depreciation is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $541.78, compared to a current price of $244.32 — trading 54.9% below its estimated fair value. The current Accumulated Depreciation is $ Mil. Alnylam Pharmaceuticals' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Accumulated Depreciation is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of $244.32 is trading 54.9% below its estimated GF Value™ of $541.78. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for LTS:0HD2:

  • Accumulated Depreciation: $ Mil
  • GF Value™: $541.78 vs. price of $244.32 (54.9% below fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, that develops RNA interference (RNAi) therapeutics, a class of drugs that silence specific genes by targeting messenger RNA. Its marketed products include Amvuttra and Onpattro for hereditary transthyretin-mediated amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria type 1. The company also earns revenue through partnerships, including Leqvio for hypercholesterolemia with Novartis and Qfitlia for hemophilia with Sanofi. Alnylam sells primarily in the United States, Europe, and other international markets, generating revenue from product sales, collaboration and license agreements, and royalties. Its pipeline spans cardio-metabolic, central nervous system, and hematology indications, and it invests heavily in research and development to expand its RNAi platform.
65GF Score

Get the complete analysis for LTS:0HD2

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$244.32
Price
$541.78
GF Value